Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Calidi Biotherapeutics, Inc.CLDI · Entity 8408 | Director | August 17, 2026 | August 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Calidi Biotherapeutics, Inc.
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2036-08-17 | Direct | 4,000 |
Reported balance
After 2026-08-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-17 · Grant · Acquired 4,000 · Balance 4,000 F1: On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 4,000 shares of common stock (the "Options") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan. F2: Does not include the stock options previously granted to the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 4,000 shares of common stock (the "Options") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan.
F2: Does not include the stock options previously granted to the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 19, 2026 23:00 UTC | Calidi Biotherapeutics, Inc. CLDI · Entity 8408 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 4,000 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001493152-26-039290 · ownership.xml · derivative · entry 1 Leftwich Scott · CIK 0001991668 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2036-08-17 F1 · security: On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 4,000 shares of common stock (the "Options") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan. F1 · derivative.exercise_date: On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 4,000 shares of common stock (the "Options") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan. F2 · balance_after: Does not include the stock options previously granted to the Reporting Person. Read SEC document |
| August 21, 2025 Filed Aug 26, 2025 00:47 UTC | Calidi Biotherapeutics, Inc. CLDI · Entity 8408 | PurchaseWarrant (right to buy) · Derivative | 125,000 | Not disclosed Strike: $2.00 | Not disclosed |
DisclosureSEC source: 0001641172-25-025446 · ownership.xml · derivative · entry 4 Leftwich Scott · CIK 0001991668 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common stock · 125,000 shares Expires 2030-08-21 F1 · kind: The common stock and warrants were acquired by the reporting person in a public offering conducted by the Issuer that was closed on August 21, 2025. F2 · price: Each common share was purchased with an accompanying warrant for a purchase price of $2.00 per share and accompanying warrant. Read SEC document |
| August 21, 2025 Filed Aug 26, 2025 00:47 UTC | Calidi Biotherapeutics, Inc. CLDI · Entity 8408 | PurchaseCommon Stock | 125,000 | $2.00 | $250,000.00 |
DisclosureSEC source: 0001641172-25-025446 · ownership.xml · nonDerivative · entry 1 Leftwich Scott · CIK 0001991668 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,650 F1 · kind: The common stock and warrants were acquired by the reporting person in a public offering conducted by the Issuer that was closed on August 21, 2025. F2 · price: Each common share was purchased with an accompanying warrant for a purchase price of $2.00 per share and accompanying warrant. Read SEC document |
| July 09, 2025 Filed Jul 16, 2025 00:42 UTC | Calidi Biotherapeutics, Inc. CLDI · Entity 8408 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 137,078 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001641172-25-019800 · ownership.xml · derivative · entry 1 Leftwich Scott · CIK 0001991668 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,078 Underlying: Common Stock · 137,078 shares Expires 2035-07-09 F1 · security: On July 15, 2025, the Reporting Person was issued a non-qualified stock option to purchase 137,078 shares of common stock (the "Options") at an exercise price of $0.70 per share (equal to the closing price on the grant date, July 9, 2025) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan. F1 · derivative.exercise_date: On July 15, 2025, the Reporting Person was issued a non-qualified stock option to purchase 137,078 shares of common stock (the "Options") at an exercise price of $0.70 per share (equal to the closing price on the grant date, July 9, 2025) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:25 UTC | Calidi Biotherapeutics, Inc. CLDI · Entity 8408 | GrantCommon Stock | 11,684 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-25-000302 · ownership.xml · nonDerivative · entry 1 Leftwich Scott · CIK 0001991668 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,774 F1 · price: Represents a grant of restricted stock units ("RSUs") on December 31, 2024 (the "Grant Date"), pursuant to the Issuer's 2023 Equity Incentive Plan and subject to the conditions of a Restricted Stock Unit Award Agreement, in a transaction exempt under Rule 16b-3 to the Reporting Person, who is a non-employee director with the Issuer, in connection with a payment in lieu of cash for services during the Issuer's fourth fiscal quarter. Each RSU represents a contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The RSUs fully vested on the Grant Date. The price per share at which the grants were issued is $1.15 and was determined based on the Issuer's closing price on December 31, 2024. Read SEC document |
| September 20, 2024 Filed Oct 16, 2024 01:14 UTC | Calidi Biotherapeutics, Inc. CLDI · Entity 8408 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 20,217 | Not disclosed Strike: $1.09 | Not disclosed |
DisclosureSEC source: 0001493152-24-041199 · ownership.xml · derivative · entry 1 Leftwich Scott · CIK 0001991668 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,217 Underlying: Common stock · 20,217 shares Expires 2034-09-20 F1 · deemedExecutionDate: On October 11, 2024, pursuant to the issuer's 2023 Equity Incentive Plan, the reporting person was issued a non-qualified stock option to purchase 20,217 shares of common stock (the "Options") at an exercise price of $1.09, which is the closing price of the issuer's common stock on the grant date, September 20, 2024 (the "Grant Date"). The Options shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the Grant Date. F1 · kind: On October 11, 2024, pursuant to the issuer's 2023 Equity Incentive Plan, the reporting person was issued a non-qualified stock option to purchase 20,217 shares of common stock (the "Options") at an exercise price of $1.09, which is the closing price of the issuer's common stock on the grant date, September 20, 2024 (the "Grant Date"). The Options shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the Grant Date. F1 · price: On October 11, 2024, pursuant to the issuer's 2023 Equity Incentive Plan, the reporting person was issued a non-qualified stock option to purchase 20,217 shares of common stock (the "Options") at an exercise price of $1.09, which is the closing price of the issuer's common stock on the grant date, September 20, 2024 (the "Grant Date"). The Options shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the Grant Date. F1 · derivative.exercise_date: On October 11, 2024, pursuant to the issuer's 2023 Equity Incentive Plan, the reporting person was issued a non-qualified stock option to purchase 20,217 shares of common stock (the "Options") at an exercise price of $1.09, which is the closing price of the issuer's common stock on the grant date, September 20, 2024 (the "Grant Date"). The Options shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the Grant Date. Read SEC document |
| June 28, 2024 Filed Jul 3, 2024 00:22 UTC | Calidi Biotherapeutics, Inc. CLDI · Entity 8408 | GrantCommon Stock | 67,187 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-026117 · ownership.xml · nonDerivative · entry 1 Leftwich Scott · CIK 0001991668 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 560,873 F1 · price: Represents a grant of restricted stock units ("RSUs") on June 28, 2024 (the "Grant Date"), pursuant to the Issuer's 2023 Equity Incentive Plan and subject to the conditions of a Restricted Stock Unit Award Agreement, in a transaction exempt under Rule 16b-3 to the Reporting Person, who is a non-employee director with the Issuer, in connection with services for the Issuer's second fiscal quarter. Each RSU represents a contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The RSUs fully vested on the Grant Date. Read SEC document |
| March 29, 2024 Filed Jul 3, 2024 00:16 UTC | Calidi Biotherapeutics, Inc. CLDI · Entity 8408 | GrantCommon Stock | 23,783 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-026111 · ownership.xml · nonDerivative · entry 1 Leftwich Scott · CIK 0001991668 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 493,686 F1 · price: Represents a grant of restricted stock units ("RSUs") on March 29, 2024 (the "Grant Date"), pursuant to the Issuer's 2023 Equity Incentive Plan and subject to the conditions of a Restricted Stock Unit Award Agreement, in a transaction exempt under Rule 16b-3 to the Reporting Person, who is a non-employee director with the Issuer, in connection with services for the Issuer's first fiscal quarter. Each RSU represents a contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The RSUs fully vested on the Grant Date. Read SEC document |
| December 21, 2023 Filed Jan 5, 2024 00:49 UTC | Calidi Biotherapeutics, Inc. CLDI · Entity 8408 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 70,249 | Not disclosed Strike: $1.80 | Not disclosed |
DisclosureSEC source: 0001493152-24-001132 · ownership.xml · derivative · entry 2 Leftwich Scott · CIK 0001991668 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,249 Underlying: Common stock · 70,249 shares Expires 2033-12-21 F1 · price: Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"), on December 21, 2023 (the "Grant Date"), the Reporting Person was granted 70,249 Non-Qualified Stock Options (the "Options") at an exercise price of $1.80, which is equal to the closing price of the Issuer's common stock on December 21, 2023, for serving as a director. Options will vest in one year or at the next annual shareholder meeting, whichever occurs first. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person. F1 · derivative.exercise_date: Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"), on December 21, 2023 (the "Grant Date"), the Reporting Person was granted 70,249 Non-Qualified Stock Options (the "Options") at an exercise price of $1.80, which is equal to the closing price of the Issuer's common stock on December 21, 2023, for serving as a director. Options will vest in one year or at the next annual shareholder meeting, whichever occurs first. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person. Read SEC document |
| December 21, 2023 Filed Jan 5, 2024 00:49 UTC | Calidi Biotherapeutics, Inc. CLDI · Entity 8408 | GrantCommon Stock | 8,958 | $1.80 | $16,124.40 |
DisclosureSEC source: 0001493152-24-001132 · ownership.xml · nonDerivative · entry 1 Leftwich Scott · CIK 0001991668 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 469,903 F2 · shares: Represents a grant of restricted stock units ("RSUs") subject to the conditions of the Restricted Stock Unit Award Agreement pursuant to the Issuer's 2023 Plan. Each RSU represents a right to receive one share of the Company's common stock upon vesting. The number of RSUs to be issued will equal to the amount due to the director for Board fees divided by the closing price for a share of the Issuer's common stock of $1.80. The RSUs were granted in a transaction exempt under Rule 16b-3 to the Reporting Person. The shares of common stock underlying the RSUs immediately vested on the Grant Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.